C90.10 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM C90.10 became effective on October 1, 2018. This is the American ICD-10-CM version of C90.10 - other international versions of ICD-10 C90.10 may differ.
C90.00 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM C90.00 became effective on October 1, 2018. This is the American ICD-10-CM version of C90.00 - other international versions of ICD-10 C90.00 may differ.
C90.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. The 2022 edition of ICD-10-CM C90.0 became effective on October 1, 2021. This is the American ICD-10-CM version of C90.0 - other international versions of ICD-10 C90.0 may differ.
The 2022 edition of ICD-10-CM C91.0 became effective on October 1, 2021. This is the American ICD-10-CM version of C91.0 - other international versions of ICD-10 C91.0 may differ. All neoplasms are classified in this chapter, whether they are functionally active or not.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
Malignant neoplasm of plasma cells usually arising in the bone marrow and manifested by skeletal destruction, bone pain, and the presence of anomalous immunoglobulins. Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes. Primary malignant neoplasms overlapping site boundaries.